COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,440 Articles (22,835 medRxiv, 8,605 bioRxiv)

Most recent first Previous |  Page 47: Articles 461-470  | Next

PM2.5 Exposure Facilitates SARS-CoV-2 Infection through ACE2/TMPRSS2 Regulation and Suppression of Anti-Viral Response
Rajabi, H., Kayalar, O., Esken, G., Can, F., Bayram, H.
10.1101/2025.10.02.679237 — Posted: 2025-10-03
Computational Analysis of Silent Mutation Effects on SARS-CoV-2 RNA-Host RNA-Binding Protein Interactome
Bello, A. J., Chukwudozie, O. S., Oladapo, O. B., Omotuyi, A. O., Nzoniwu, N. A., Amusa, O. D., Ottu, B. O., Okeke, U., Adewole, A. O., Akinnusi, O. O., Kade, A. E., Minari, J. B., Okpuzor, J., Folarin, O., Shittu, M. O.
10.1101/2025.09.22.677528 — Posted: 2025-10-03
IgG4 Neutralization and Sustained Total IgG Fc-Effector Functions Following Repeated SARS-CoV-2 mRNA Vaccination
Kaplonek, P., Bertera, H., Lee, D. W., Cizmeci, D., Yu, W.-H., Wu, K., Chalkias, S., Wahid, R., Edwards, D. K., Alter, G., Henry, C.
10.1101/2025.09.30.25336755 — Posted: 2025-10-02
Dynamical survival analysis for epidemic modeling under partial observability: A case study of COVID-19 in Kenya
KAGUNDA, J. W., Gothard, A., Rempala, G., Choi, B.
10.1101/2025.09.30.25337023 — Posted: 2025-10-02
Quantifying SARS-CoV-2 Omicron variant spread and the impact of non-pharmaceutical interventions in Newfoundland and Labrador, Canada
Anokye, F., Li, M. W., Walker, S., Hurford, A.
10.1101/2025.09.26.25336738 — Posted: 2025-10-02
Leveraging Multimodal Large Language Models to Extract Mechanistic Insights from Biomedical Visuals: A Case Study on COVID-19 and Neurodegenerative Diseases
Popova, E., Jacobs, M., Hofmann-Apitius, M., Babaiha, N. S.
10.1101/2025.10.01.679928 — Posted: 2025-10-02
Memory B cell Development in Response to mRNA SARS-CoV-2 and Nanoparticle Immunization in Mice
Wiatr, m., wang, z., Canis, M., Gazumyan, A., hernandez, B., Santos, G. S., Shawraz, S., lee, S., Bieniasz, P. D., Hatziioannou, T., Muecksch, F., Nussenzweig, M. C.
10.1101/2025.10.01.679787 — Posted: 2025-10-02
Directed evolution of a stem-helix targeting antibody enables MERS-CoV cross-neutralization through enhanced binding affinity
Zhou, P., Yuan, M., Zhang, Y., Limbo, O., Song, G., Zhao, F., Liu, H., He, W.-t., Capozzola, T., Callaghan, S., Avillion, G., Li, X., Beutler, N., Yong, P., Anzanello, F., Rogers, T. F., Burton, D. R., Jardine, J. G., Wilson, I. A., Andrabi, R.
10.1101/2025.10.02.680065 — Posted: 2025-10-02
Glycans modulate the adsorption of RBD Glycoproteins on polarizable surfaces
Bosch, A., Menacho, W., Perez, R., V. Guzman, H. V.
10.1101/2025.09.30.679433 — Posted: 2025-10-01
Enhanced human antigen-specific B cell responses using in vitro 3D tonsil cultures containing stromal cells
Braham, M. V. J., de Gast, M., Babii, L., Kruijer, S., Bestebroer, T. M., Richard, M., Claireaux, M., van Ham, M. S., de Wit, J., van Els, C. A. C. M., ten Brinke, A., van Gils, M.
10.1101/2025.09.30.679470 — Posted: 2025-10-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).